High-dose IL-2 has shown anti-tumor activity in patients with metastatic melanoma but with high rate of serious adverse events; BEMPEG was engineered to increase the half-life of IL-2 allowing for less frequent dosing and a more favorable safety profile. The gene discussed is IL2; the disease is neoplasm.